We are live on ! Find out more
EW icon

Edwards Lifesciences

1,279 hedge funds and large institutions have $46.6B invested in Edwards Lifesciences in 2024 Q1 according to their latest regulatory filings, with 159 funds opening new positions, 436 increasing their positions, 462 reducing their positions, and 106 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more funds holding in top 10

Funds holding in top 10: 914 (+5)

50% more first-time investments, than exits

New positions opened: 159 | Existing positions closed: 106

25% more capital invested

Capital invested by funds: $37.3B → $46.6B (+$9.28B)

3% more funds holding

Funds holding: 1,2441,279 (+35)

10% more call options, than puts

Call options by funds: $431M | Put options by funds: $393M

0.75% more ownership

Funds ownership: 80.51%81.25% (+0.75%)

6% less repeat investments, than reductions

Existing positions increased: 436 | Existing positions reduced: 462

Holders
1,279
Holders Change
+35
Holders Change %
+2.81%
% of All Funds
18.42%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
159
Increased
436
Reduced
462
Closed
106
Calls
$431M
Puts
$393M
Net Calls
+$38.1M
Net Calls Change
-$65.8M
Name Holding Trade Value Shares
Change
Change in
Stake
VLKIM
176
Van Lanschot Kempen Investment Management
Netherlands
$21.4M +$18.8M +224,109 New
Natixis Advisors
177
Natixis Advisors
Massachusetts
$21.2M -$459K -5,470 -2%
CAG
178
Crestwood Advisors Group
Massachusetts
$21M -$148K -1,756 -0.8%
SP
179
Sarasin & Partners
United Kingdom
$20.7M -$1.33M -15,830 -7%
TAF
180
Tredje AP-fonden
Sweden
$20.7M +$3.95M +47,000 +28%
RAM
181
Resona Asset Management
Japan
$20.4M +$17.9M +213,622 New
Cerity Partners
182
Cerity Partners
New York
$20.3M -$14.1M -168,074 -44%
Stifel Financial
183
Stifel Financial
Missouri
$20.3M -$1.89M -22,549 -10%
Rockefeller Capital Management
184
Rockefeller Capital Management
New York
$20.2M +$1.21M +14,434 +7%
GC
185
Guggenheim Capital
Illinois
$20.2M +$343K +4,086 +2%
Two Sigma Advisers
186
Two Sigma Advisers
New York
$19.9M -$106M -1,265,197 -86%
BCAM
187
Boston Common Asset Management
Massachusetts
$19.6M -$1.75M -20,836 -9%
NP
188
NS Partners
United Kingdom
$19.5M -$338K -4,027 -2%
GIA
189
Gateway Investment Advisers
Ohio
$19.4M -$4.18M -49,813 -20%
2
190
2Xideas
Switzerland
$18.8M +$3.4M +40,465 +26%
VMPIC
191
Varma Mutual Pension Insurance Co
Finland
$18.8M +$9.97M +118,700 +153%
Mirae Asset Global Investments
192
Mirae Asset Global Investments
South Korea
$18.8M +$330K +3,927 +2%
DnB Asset Management
193
DnB Asset Management
Norway
$18.8M -$3.93M -46,795 -19%
EAM
194
Erste Asset Management
Austria
$18.4M
ECM
195
ExodusPoint Capital Management
New York
$18M +$15.9M +188,747 New
GWM
196
GDS Wealth Management
Texas
$17.9M +$455K +5,418 +3%
ONB
197
Old National Bancorp
Indiana
$17.7M -$61K -726 -0.4%
National Bank of Canada
198
National Bank of Canada
Quebec, Canada
$17.6M -$977K -11,625 -5%
CL
199
CIM LLC
New York
$17.6M +$347K +4,135 +2%
DZ Bank
200
DZ Bank
Germany
$17.4M -$25.7M -306,021 -63%

EW Hedge Fund Activity: Q1 2024 in Review

1,279 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2024, worth a combined $46.6B — up 25% from $37.3B a quarter earlier.

Buyers outnumbered sellers: 159 funds opened new EW positions and 106 closed out — a net gain of 53 holders — while 436 added to existing stakes and 462 trimmed.

The largest buyer was Winslow Capital Management, opening a new position worth an estimated $425M. The largest seller was Capital International Investors, cutting an estimated $573M.

  • 1,279 institutional investors held Edwards Lifesciences (EW) as of Q1 2024, up from 1,244 in Q4 2023.
  • Funds reported $46.6B of Edwards Lifesciences stock for Q1 2024, up 25% quarter-over-quarter.
  • 159 funds opened new Edwards Lifesciences positions in Q1 2024 and 106 closed out, a net change of +53 holders.
  • The largest Edwards Lifesciences buyer in Q1 2024 was Winslow Capital Management, an estimated $425M added.
  • The largest Edwards Lifesciences seller in Q1 2024 was Capital International Investors, an estimated $573M sold.

Based on aggregated 13F filings for Q1 2024.